Pembrolizumab is recommended, within its marketing authorisation, as an option for the adjuvant treatment of non-small-cell lung cancer (NSCLC) with a high risk of recurrence after complete resection ...

At the final analysis, the coprimary endpoint of overall survival was not met. Topline data were announced from a phase 3 trial evaluating pembrolizumab (Keytruda ®) plus lenvatinib (Lenvima ...

This trial is looking at adding SCIB1 or iSCIB1+ to nivolumab and ipilimumab for melanoma. It is also looking at adding SCIB1 to pembrolizumab for melanoma. It is for people whose melanoma has grown ...